Safety and Efficacy Study of Oral Zabofloxacin in Community Acquired Pneumonia

A Phase 2, Multi-Dose, Double-Blind, Double-Dummy, Active-Control, Randomized Study to Evaluate the Safety, Efficacy and Pharmacokinetic Profile of Two Dosing Regimens of Zabofloxacin for the Treatment of Community-Acquired Pneumonia of Moderate Severity

A double-blind, three-arm study, to evaluate the safety and efficacy of two dosing regimens of zabofloxacin (a fluoroquinolone antibiotic) in community acquired pneumonia.

Study Overview

• Status: Terminated
• Conditions: Community Acquired Pneumonia
• Intervention / Treatment: Drug: Levofloxacin 500mg; Drug: Zabofloxacin 400mg; Drug: Zabofloxacin

Detailed Description

The study is a Phase 2, global, prospective, multi-dose, double-blind, double-dummy, active-control, randomized, parallel-group, multicenter study of oral zabofloxacin HCl (400mg) versus oral levofloxacin (500mg) in the treatment of adults with community-acquired pneumonia of moderate severity.

• Study Type: Interventional
• Enrollment (Actual): 48
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Alabama
    • Huntsville, Alabama, United States, 35801
    • Toney, Alabama, United States, 35773
  • Florida
    • Ft. Myers, Florida, United States, 33916
  • Idaho
    • Eagle, Idaho, United States, 93616
  • Indiana
    • Evansville, Indiana, United States, 47714
  • Michigan
    • Keego Harbor, Michigan, United States, 48320
  • New Jersey
    • Belvidere, New Jersey, United States, 078238
  • Ohio
    • Columbus, Ohio, United States, 43214
    • Dayton, Ohio, United States, 45432
    • Springfield, Ohio, United States, 45504
  • Oregon
    • Gresham, Oregon, United States, 97030
  • Pennsylvania
    • Warminster, Pennsylvania, United States, 18974
  • Texas
    • Tyler, Texas, United States, 75708

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male or female >/= 18 years old
• Documented fever (oral >100°F (37.8°C), tympanic >101°F (38.1°C)must be documented within the time frame of 24 hours prior to first dose through 24 hours after first dose of study drug
• Community-acquired pneumonia of moderate severity (defined as PSI Risk Class II or III) requiring administration of antibiotics
• Dyspnea and/or tachypnea (>20 breaths/minute)

• Clinical diagnosis of pneumonia, as demonstrated by all of the following signs and symptoms:

  1. new or increased cough
  2. production of purulent sputum or a change in the character of sputum in subjects who normally have purulent sputum
  3. auscultatory findings on pulmonary examination of rales and/or evidence of pulmonary consolidation (e.g., bronchial breath sounds, egophony, or dullness on percussion)
• Females must be surgically sterile (e.g., tubal ligation, hysterectomy), post-menopausal at least 2 years, or if of childbearing potential, they must have a negative urine pregnancy test (β-human chorionic gonadotropin [β-hCG]) prior to randomization into the study. Males and females must agree that if they have intercourse that they will use at least two medically accepted methods of birth control (e.g., hormonal contraceptive, intrauterine device, spermicide, or condom) from study entry through 60 days after discontinuation of study drug treatment
• Able to give written informed consent in a manner approved by the Institutional Review Board or Ethics Committee and comply with the requirements of the study

Exclusion Criteria:

Subjects must NOT meet any of the following exclusion criteria:

• Received one or more doses of any systemic antibiotic in the last 2 weeks
• Diagnosed with any other infection requiring systemic antibacterial therapy
• Require long-term (>7 days) antibiotic therapy
• Previous diagnosed condition that might mimic or complicate the course and evaluation of the infectious disease process (e.g., septic shock, bronchiectasis, lung abcess or empyema, aspiration pneumonia, active tuberculosis, pulmonary malignancy, cystic fibrosis, post-obstructive pneumonia, etc.)
• Hypothermia (oral <96°F [35.6°C}, tympanic <97°F [35.9°C]
• Hospitalization (inpatient) in the previous 60 days or infection presumably acquired in the hospital
• Resident of a skilled nursing facility anytime in the previous 60 days or infection presumably acquired in a skilled nursing facility
• Chronic infection with Hepatitis B
• Any evidence of, or is a known carrier of , Hepatitis C antibody
• Infection with Clostridium difficile
• Immunocompromising illness, including known human immunodeficiency virus (HIV) positivity or AIDS, organ (bone marrow) transplant recipients, and hematological malignancy
• Psychotic disease, peripheral neuropathy, and glucose-6-phosphate dehydrogenase deficiency; uncontrolled or poorly controlled diabetes. Diabetic subjects who are stable and on a stable course of antihyperglycemic agents for the past 3 months will be permitted in the trial.
• High exposure to sunlight or ultraviolet radiation
• Immunosuppressive therapy, including cancer chemotherapy or chronic use of corticosteroids (i.e., >20mg prednisone or equivalent per day for >/= 14 days within the last 6 months

• History of renal or hepatic disease as defined by at least one of the following:

  1. Calculated creatinine clearance <50 mL/min (any subject on dialysis must be excluded)
  2. BUN >/= 30 mg/dL
  3. ALT or AST > 3x ULN
  4. Total bilirubin > 2x ULN
  5. Alkaline phosphatase > 1.25x ULN
• History of or current malabsorption conditions (i.e., short bowel syndrome, active Crohn's disease, celiac disease, etc.)
• Neutropenia as defined by absolute neutrophil count <1000 cells/mm3. Subjects with neutrophil counts as low as 500 cells/mm3 are permitted if the reduction can be documented to be due to the acute infectious process
• Platelet count <75,000/mm3. Subjects with platelet counts as low as 50,000/mm3 are permitted if the reduction is historically stable
• Coagulation tests >1.5x ULN (PT, PTT, or INR). Subjects on anticoagulants with values > 1.5x ULN can be enrolled, provided these values are historically stable and within the therapeutic range
• History of alcohol or drug abuse in the past 2 years
• History of seizure or currently receiving anti-seizure medication anytime in the past year, or a seizure in the past year
• History of ventricular arrhythmia
• History of QTc prolongation (i.e., >450msec) or observed QTc measurement at screening > 450msec, or a history of additional risk factors for Torsade de Pointe, such as heart failure, hypokalemia, or familial history of Long QT syndrome
• Require medications that may prolong the QTc interval
• Require medications that affect absorption, including but not limited to sucralfate or cimetidine
• Require treatment with theophylline, probenecid, vitamin K antagonists (other than warfarin; subjects must be on stable dose of warfarin and within therapeutic range)
• Pregnant, planning to become pregnant, or breast feeding
• Received any investigational drug or device within 30 days prior to study entry
• Previously received zabofloxacin in a clinical trial
• History of allergy or intolerability to fluoroquinolones
• History of fluoroquinolone tendinopathy
• Evidence of immediately life-threatening disease including, but not limited to current or impending respiratory failure, acute heart failure, shock, acute coronary syndrome, unstable arrhythmias, hypertensive emergency, acute hepatic failure, active gastrointestinal bleeding, profound metabolic abnormalities (e.g., diabetic ketoacidosis), or acute cerebrovascular events
• Current condition or abnormality that, in the opinion of the investigator, would compromise the safety of the subject or the quality of the data
• Unable or unwilling to adhere to sthe study specified procedures and restrictions

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: TRIPLE

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
ACTIVE_COMPARATOR: Levofloxacin 500mg; Levofloxacin 500mg once daily for 7 days	Drug: Levofloxacin 500mg; Levofloxacin 500mg orally for 7 days
EXPERIMENTAL: Zabofloxacin 5 days; Zabofloxacin 400mg for 5 days	Drug: Zabofloxacin 400mg; Zabofloxacin 400mg orally for 5 days
EXPERIMENTAL: Zabofloxacin 3 days; Zabofloxacin 400mg for 3 days	Drug: Zabofloxacin; Zabofloxacin 400mg capsule once daily for 3 days

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety	Assess safety through monitoring of adverse events, ECGs, and the collection of conventional laboratory data (i.e., chemistry panel, CBC with differential, urinalysis)	Up to 35 days after first dose

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Efficacy of the two dosing regimens of zabofloxacin	Determine the clinical response and microbiological response of two dosing regimens in the treatment of bacteriologically confirmed CAP of moderate severity; determine the pharmacokinetic profile in subjects with CAP.	Up to 35 days after first dose

Collaborators and Investigators

• Sponsor: IASO Pharma Inc.

Study record dates

Study Major Dates

• Study Start: March 1, 2010
• Primary Completion (ACTUAL): April 1, 2012
• Study Completion (ANTICIPATED): June 1, 2012

Study Registration Dates

• First Submitted: February 19, 2010
• First Submitted That Met QC Criteria: March 4, 2010
• First Posted (ESTIMATE): March 5, 2010

Study Record Updates

• Last Update Posted (ESTIMATE): May 7, 2012
• Last Update Submitted That Met QC Criteria: May 4, 2012
• Last Verified: May 1, 2012

More Information

Terms related to this study

• Keywords: pneumonia; Community acquired pneumonia of moderate severity
• Additional Relevant MeSH Terms: Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Lung Diseases; Pneumonia; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Nucleic Acid Synthesis Inhibitors; Enzyme Inhibitors; Antineoplastic Agents; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Anti-Bacterial Agents; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors; Anti-Infective Agents, Urinary; Renal Agents; Levofloxacin; Ofloxacin; Fluoroquinolones
• Other Study ID Numbers: PB-101-200